Cantor Fitzgerald Reiterates Overweight on Celldex Therapeutics, Maintains $54 Price Target
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Kristen Kluska has reiterated an Overweight rating on Celldex Therapeutics (NASDAQ:CLDX) and maintained a $54 price target.
October 12, 2023 | 3:52 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cantor Fitzgerald has reiterated an Overweight rating on Celldex Therapeutics and maintained a $54 price target.
The reiteration of an Overweight rating by Cantor Fitzgerald indicates a positive outlook for Celldex Therapeutics. The maintained price target of $54 suggests that the analyst believes the stock has potential for growth. This could positively impact the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100